UNASSIGNED: Various source-derived mesenchymal stem cells (MSCs) with multipotent capabilities were considered for cell therapeutics of incurable diseases. The applicability of MSCs depends on the cellular source and on their different in vivo functions, despite having similar phenotypic and cytological characteristics. We characterized MSCs from different sources, including @entity1 bone marrow (BM), placenta (PL), and @entity1386 ( @entity1386 ), in terms of the phenotype, surface antigen expression, differentiation ability, proteome reference map, and blood flow recovery in a hindlimb @entity63 model. The MSCs exhibit different differentiation potentials depending on the cellular source despite having similar phenotypic and surface antigen expression. We identified approximately 90 differentially regulated proteins. Most up- or down-regulated proteins show cytoskeletal or oxidative stress, peroxiredoxin, and apoptosis roles according to their functional involvement. In addition, the PL-MSCs retained a higher therapeutic efficacy than the BM- and @entity1386 in the hindlimb @entity63 model. In summary, we examined differentially expressed key regulatory factors for MSCs that were obtained from several cellular sources and demonstrated their differentially expressed proteome profiles. Our results indicate that primitive PL-MSCs have biological advantages relative to those from other sources, making PL-MSCs a useful model for clinical applications of cell therapy. J. Cell. Biochem. 9999: 1-14, 2015.    2015 Wiley Periodicals, Inc.

Comparative Analysis of XXXX Mesenchymal Stem Cells Derived from Bone Marrow, Placenta, and Adipose Tissue as Sources of Cell Therapy.

@entity1 :: ('9606', 'Species') :: ['human'] @entity1386 :: ('MESH:D018205', 'Disease') :: ['AT-MSCs', 'adipose tissue', 'AT'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic disease']
@entity1 :: (9606,Species) :: ['Human']
